Merck Sharp + Dohme Corp.

Schering Corporation

Schering-Plough Corporation

Joel M Harris

Andrew William Stamford

Bernard R Neustadt

Hong Liu

Michael W Miller

Craig D Boyle

Duane E DeMong

Jinsong Hao

William J Greenlee

Samuel Chackalamannil

Brian Alexander McKittrick

Jack D Scott

Elizabeth M Smith

Marc Poirier

Unmesh G Shah

Chad E Bennett

Kallol Basu

Chad E Knutson

Claire Lankin

Hyunjin M Kim

Eugenia Y Kiselgof

John M Sanders

Anandan Palani

Duane A Burnett

Robert G Aslanian

John A McCauley

Scott D Edmondson

Dong Xiao

Xing Dai

Yan Xia

Ping Liu

Thomas J Greshock

Deen Tulshian

Gregori J Morriello

Cheng Zhu

Harold B Wood

Bowei Wang

Tin-Yau Chan

Milana M Maletic

Santhosh Francis Neelamkavil

Wanying Sun

Rajan Anand

Paul Tempest

Liping Wang

William Bert Geiss

Lehua Chang

Yuping Zhu

Vincent Colandrea

Henry M Vaccaro

Zhiqiang Guo

Zhiyong Hu

Nam Fung Kar

Jason W Szewczyk

Kake Zhao

Heather E Stevenson

Wei Li

Yong Huang

Peter Korakas

Jonathan T Kern

Megan Macala

Charles Lee Jayne

John A Mccauley

Michael Miller

Duane E Demong

William B Geiss

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Compounds inhibiting leucine-rich repeat kinase enzyme activity

The present invention relates to Bridged Bicyclic Piperidine Derivatives, compositions comprising a Bridged Bi-cyclic Piperidine Derivative, and methods of using the Bridged Bicyclic Piperidine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

Bridged bicyclic piperidine derivatives and methods of use thereof

The present invention relates to Substituted Biaryl Derivatives, compositions comprising a Substituted Biaryl Derivative, and methods of using the Substituted Biaryl Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

Substituted biaryl derivatives and methods of use thereof

Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. 

Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment

The present invention relates to certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the 'Fused Tricyclic Compounds'), wherein M, Q, U, W, X, Y, Z, R, R, and R, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease. 

Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists

Compounds of the Formula (I), where W represents CH or N; and Q represents &#x2014;CN, &#x2014;C(&#x2550;NOH)NH, &#x2014;CONHRor various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine Areceptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease. 

[object Object]

The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.

Bicyclic heterocycle derivatives and methods of use thereof

Compounds of the Formula I wherein Rand Rtogether with the carbon atoms to which they are bonded optionally form a further heteroaromatic ring of the formula (II) as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease. 

The present invention relates to Azetidinone Derivatives of structural formula 1: and compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.

Azetidinone derivatives and methods of use thereof

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein

Disclosed are compounds of the formula: and compounds of the formula: wherein R, R, R, R, R, u and v are as defined herein. Also disclosed are methods of treating pain (e.g., inflammatory pain, chronic pain, and neuropathic pain), methods of treating diabetes, and methods of inhibiting the absorption of cholesterol using compounds of formula I or IIA.

Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism

2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Growing community of inventors

Blaine, MN, United States of America

Joel M Harris